FDA Warns LabCorp About 'Misbranded' OvaSure Test | GenomeWeb
NEW YORK (GenomeWeb News) - Nearly one year after the US Food and Drug Administration slammed Exact Sciences for misbranding a genetic colorectal cancer screening assay it was developing with the Laboratory Corporation of America as a laboratory-developed test, LabCorp is facing regulatory action from the agency for the same violation for an ovarian cancer detection test it developed with Yale University.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.